Skip to main content
PMC home page
eLife logoLink to eLife
. 2018 Aug 14;7:e35314. doi: 10.7554/eLife.35314

The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer

Alison Caldwell 1,2, Rachel Coleby 1,2, Cesar Tovar 3, Maximilian R Stammnitz 4, Young Mi Kwon 4, Rachel S Owen 1, Marios Tringides 1, Elizabeth P Murchison 4, Karsten Skjødt 5, Gareth J Thomas 2,6, Jim Kaufman 4,7, Tim Elliott 2,6, Gregory M Woods 3, Hannah VT Siddle 1,2,✉
Editors: Arup K Chakraborty8, Ronald N Germain9
PMCID: PMC6092122  PMID: 30103855

Abstract

Devil Facial Tumour 2 (DFT2) is a recently discovered contagious cancer circulating in the Tasmanian devil (Sarcophilus harrisii), a species which already harbours a more widespread contagious cancer, Devil Facial Tumour 1 (DFT1). Here we show that in contrast to DFT1, DFT2 cells express major histocompatibility complex (MHC) class I molecules, demonstrating that loss of MHC is not necessary for the emergence of a contagious cancer. However, the most highly expressed MHC class I alleles in DFT2 cells are common among host devils or non-polymorphic, reducing immunogenicity in a population sharing these alleles. In parallel, MHC class I loss is emerging in vivo, thus DFT2 may be mimicking the evolutionary trajectory of DFT1. Based on these results we propose that contagious cancers may exploit partial histocompatibility between the tumour and host, but that loss of allogeneic antigens could facilitate widespread transmission of DFT2.

Research organism: Other

eLife digest

While cancer cells typically cannot spread between individuals, there are a few examples of contagious tumours. Remarkably, two examples have emerged in a single species, the Tasmanian devil, a marsupial carnivore. These tumours are known as Devil Facial Tumour 1 (or DFT1) and Devil Facial Tumour 2 (or DFT2); both cause tumours round the faces of infected devils. Since it emerged in the 1990s, DFT1 has killed 60–90% of the devil population. Preserving the few remaining healthy devils has been a major challenge for conservationists. This challenge became more urgent in 2014, when the second contagious cancer, DFT2, was discovered circulating in the population.

Contagious cancers are rare because the immune system usually eliminates cells coming from outside the body. Each healthy cell carries molecules known as the major histocompatibility complex (MHC) that act as a barcode showing where each cell comes from. The immune system uses these molecules to help it tell the difference between the body’s own cells and those from elsewhere. DFT1 can avoid the immune system and spread to new hosts because it has lost MHC. In 2014, scientists identified a new Tasmanian devil cancer named DFT2, but it was unclear how this second cancer evades the immune system as it spreads from host to host.

Caldwell et al. have now examined the MHC on cells from DFT2 cancers, including cells grown in the laboratory and cells taken from cancer biopsies. Biochemical tests showed that the DFT2 cells do carry MHCs, but that the MHC barcodes of DFT2 are similar to those of the devils infected with the disease. This finding may explain how the cancer can spread undetected in these animals, because the immune system does not recognize it as coming from outside the body. Further analyses also reveal that the cancer cells are slowly evolving to lose their MHCs. This means DFT2 could, with time, become as contagious as DFT1.

These two contagious cancers threaten the future of the Tasmanian devil. As top predators, devils are key to the ecosystem in Tasmania and their preservation is vital. While DFT2 provides a unique opportunity to study an emerging cancer as it develops, this research will also help to protect the devils and may lead to effective vaccines. These results could also reveal how other cancers avoid the immune system and may help to detect them during treatment. In addition, there are many similarities between contagious cancer cells and organ transplants. Understanding the role of MHC in DFT2 could lead to better ways to prevent rejection following transplants.

Introduction

Contagious cancers have emerged and circulate in two species of mammals (dogs and Tasmanian devils) and four species of molluscs (Metzger et al., 2015, 2016; Novinski, 1876; Pearse and Swift, 2006). The Tasmanian devil is the only mammalian species in which two independent contagious cancers exist, Devil Facial Tumour 1 (DFT1) and Devil Facial Tumour 2 (DFT2) (Pye et al., 2016b). Although both cancers have similar gross morphology, causing tumours on the face, neck and oral cavity, genetic analysis shows that they emerged in different individuals (Pearse and Swift, 2006; Pye et al., 2016b; Stammnitz et al., 2018). DFT1 was first identified in 1996 in the northeast of Tasmania (Hawkins et al., 2006), but has since spread widely, causing close to 100% mortality and drastic decline of affected populations (Hamede et al., 2015). In contrast, DFT2 is a more recent contagious cancer, it was first characterised in 2014 and has been formally identified in eleven devils from the Channel region of Southwest Tasmania (Pye et al., 2016b; Kwon et al., 2018). Recent immunohistochemical and drug sensitivity analyses of DFT2 indicate it arose from a similar tissue to DFT1 (Stammnitz et al., 2018).

As allografts, DFT1 and DFT2 cells should be rejected by the host devil through T cell recognition of non-self MHC class I molecules encoded by the major histocompatibility complex (MHC) (Sherman and Chattopadhyay, 1993). The mature MHC class I molecule is a trimer that acts as a ligand for the T cell receptor (TCR) and is composed of a light chain, β2-microglobulin (β2m), in non-covalent association with a heavy chain, which provides a binding cleft for self and non-self peptides. Classical MHC class I molecules are important transplantation antigens that are highly polymorphic, ubiquitously expressed and involved in peptide-antigen presentation. In contrast, non-classical MHC class I molecules have little polymorphism and more diverse functions, including regulation of the immune response particularly by inhibiting natural killer (NK) cell function (Braud et al., 1999). Allografts can be rejected within 7–14 days when host CD8+ T cells are exposed to non-self MHC class I molecules and their bound peptides on the surface of donor cells (Rosenberg, 1993).

Vertebrates have multiple MHC class I genes that are generally not orthologous between species due to rapid evolution (Adams and Parham, 2001). Five MHC class I genes have been identified in the genomic region encoding the Tasmanian devil MHC (Cheng et al., 2012). Saha-UA, -UB and –UC, are likely classical, with moderate levels of polymorphism and ubiquitous expression, while Saha-UD, –UK and -UM, are non-classical, with limited polymorphism and restricted expression (Cheng et al., 2012; Cheng and Belov, 2014).

We have previously demonstrated that DFT1 cells down-regulate MHC class I and class II molecules from their cell surface, thereby removing the targets for a T cell response (Siddle et al., 2013). This is the first indication that DFT1 cells have similar immune evasion mechanisms to those found in single organism tumours (Hicklin et al., 1999; McGranahan et al., 2017). Loss of MHC class I is due to epigenetic down-regulation of β2m, and the peptide transporter encoded by TAP1 and TAP2 (Siddle et al., 2013) but MHC class I can be restored in DFT1 cells when treated with IFNγ (Siddle et al., 2013). MHC class I positive DFT1 cells have since been used with some success in initiating immune responses to DFT1 cells (Tovar et al., 2017). Down-regulation of MHC is also observed in the canine transmissible venereal tumour (CTVT), where MHC molecules are down-regulated during transmission and growth (Hsiao et al., 2002; Pérez et al., 1998). However, subsequent cytokine signalling leads to lymphocyte infiltration of tumours, MHC up-regulation and either tumour regression or stasis of growth (Yang et al., 1987). These findings have suggested that loss of MHC class I expression is necessary for the emergence and subsequent transmission of contagious cancers.

Why DFT2 cells can pass between individuals without a protective immune response from the host is not known, nor are the conditions that have facilitated the emergence of two contagious cancers in this species. Here we show that in contrast to DFT1, DFT2 cells express MHC class I molecules. However, the dominantly expressed MHC class I alleles are either non-classical or shared with host devils and common in the wider population. Finally, DFT2 tumours were identified with evidence of MHC class I loss, indicating the emergence of MHC class I down-regulation in this tumour.

Results

DFT2 cells express β2m protein, a component of the MHC class I complex

Flow cytometry using a monoclonal antibody against Tasmanian devil β2m was used to assess the level of MHC class I expression on the surface of a representative DFT1 cell line (DFT1_4906) (Figure 1A), DFT1 cells treated with IFNγ (DFT1_4906 + IFNγ) (Figure 1B), three DFT2 cell lines (DFT2_RV, DFT2_SN and DFT2_TD549) (Figure 1C,D and E) and devil fibroblast cells (Fibroblasts_Salem) (Figure 1F). As has been previously reported (Siddle et al., 2013), DFT1 cells do not express β2m, but DFT1 cells treated with IFNγ upregulate β2m to the same level as devil fibroblast cells. In contrast, all three DFT2 cell lines express cell surface β2m, but the level of expression varies, DFT2_TD549 cells have the highest level of expression (Mean Fluorescence Intensity (MFI) 42.1) followed by DFT2_RV (MFI 37.6) and DFT2_SN (MFI 12.1). Although all three DFT2 cell lines express β2m, they have lower levels of β2m than DFT1 cells that have been treated with IFNγ (MFI 92.5) and devil fibroblasts (MFI 93.3). These results indicate that DFT2 cells grown in culture express surface MHC class I molecules in contrast to DFT1, which is MHC class I negative.

Figure 1. DFT2 cells express β2m in vitro.

Figure 1.

Open in a new tab

Flow cytometry to compare β2m expression shows (A) DFT1_4906, (B) DFT1_4906 + IFNγ, (C) DFT2_RV, (D) DFT2_SN, (E) DFT2_TD549 and (F) Fibroblast_Salem cells stained with α-β2m (solid line) and secondary only control (shaded peak). DFT1_4906 + IFNγ (B) stained with blocked α-β2m antibody is also shown (dashed line). Fluorescence intensity for α-β2m on x-axis and cell counts on y-axis.

DFT2 cells express classical and non-classical MHC class I heavy chain genes in vitro and in vivo

RT-qPCR was used to quantify the relative level of MHC class I gene expression for β2m, classical MHC class I and non-classical MHC class I genes in vitro (Figure 2A–D). Due to high nucleotide similarity between the classical MHC class I genes in the Tasmanian devil, Saha-UA, -UB and –UC, and their respective alleles, a single primer set was used to amplify transcripts from these genes as a group. Gene specific primers were used to amplify the non-classical MHC class I genes, Saha-UK (Figure 2C) and Saha-UD, which was found only at trace levels (Figure 2—figure supplement 1). RT-qPCR shows that DFT2 cells express significantly higher levels of β2m (Figure 2A), classical MHC class I heavy chain genes (Saha-UA, -UB and -UC) (Figure 2B) and non-classical MHC class I (Saha-UK) (Figure 2C) than DFT1_4906. However, expression of β2m and Saha-UA, -UB and -UC by DFT2 cells is lower than that of DFT1_4906 + IFNγ and Fibroblasts, which is consistent with the levels of β2m expression observed on the DFT2 cell lines. Interestingly, while the levels of Saha-UA, -UB and -UC in the three DFT2 cell lines is lower than DFT1_4906 + IFNγ (Figure 2B and D), the levels of Saha-UK are not significantly different (Figure 2C and D). This is despite the fact that the expression level of the classical MHC class I genes reflects the amplification of three different MHC class I loci compared to a single locus, Saha-UK. Thus, DFT2 cells in vitro express both classical and non-classical MHC class I heavy chain genes.

Figure 2. DFT2 cells in vitro and in vivo express mRNA for β2m, Saha-UK, Saha-UA, UB and UC.

RT-qPCR of (A) β2m, (B) Saha-UA, -UB and -UC and (C) Saha-UK mRNA expression by DFT2 cell lines (DFT2_RV, DFT2_SN, DFT2_TD549), fibroblast cells (Fibroblasts_Salem) and DFT1 cells treated with IFNγ (DFT1_4906 + IFNγ) relative to DFT1_4906 cells. Gene expression levels are normalized against RPL13A as a housekeeping gene. Data are represented as mean ± S.E.M of three technical replicates. (D) An unpaired T-test was performed to test for statistical significance. (E) RT-PCR on DFT2 cell lines and DFT2 primary tumours for β2m, Saha-UA, -UB and -UC and Saha-UK. RPL13A was used as a loading control. A no DNA control (NDC) is included for each RT-PCR. A marker at 300 base pairs is indicated by an asterisk.

Figure 2.

Figure 2—figure supplement 1. RT-PCR amplification of RPL13A and Saha-UD from DFT1, DFT2 and Fibroblast cells.

Figure 2—figure supplement 1.

mRNA from DFT1_4906, DFT1_4906 + IFNγ, DFT2_RV-CL, DFT2_SN-CL, DFT2_TD549-CL and Fibroblast_Salem cell lines was used. A no cDNA negative control was included in each experiment.
Open in a new tab

To extend this analysis to primary DFT2 tumours we used RT-PCR to amplify β2m and MHC class I heavy chain transcripts from the DFT2 cell lines and six primary DFT2 tumours collected between March 2014 and January 2016 (Figure 2E and Supplementary file 1). The primary tumours include DFT2_RVT1 and DFT2_SNT2 from which the cell lines DFT2_RV and DFT2_SN were derived. RT-PCR shows evidence of expression for β2m in the cell lines and in primary tumour samples (Figure 2E), reflecting the expression of cell surface β2m protein in the cell lines. Saha-UK is expressed in all cell lines and primary biopsies. The cell lines and primary tumours express classical MHC class I, but the expression levels appear to be variable between the primary tumours. While this analysis is not quantitative, as the amount of stroma in each sample varies between tumours, these results show that DFT2 cells express both classical and non-classical MHC class I transcripts alongside β2m.

The expression of MHC class I molecules varies in DFT2 tumours in vivo

To further investigate the expression of MHC class I molecules between DFT2 tumours in vivo, a shared peptide immunogen was used to raise a pan-classical MHC I antibody against the classical MHC class I heavy chains (Saha-UA, -UB and -UC). A second peptide, specific in sequence to Saha-UK, was used to raise an antibody against the non-classical MHC class I, Saha-UK. Monoclonal antibodies were initially screened by western blot using protein from devil fibroblast cells. Positive clones were re-screened for molecule specificity against recombinant Saha-UK and recombinant Saha-UC protein (Figure 3—figure supplement 1). Clones specific for Saha-UK (clone - α-UK_15-29-1) and Saha-UA –UB and -UC (clone - α-UA/UB/UC_15-25-18) were identified.

Staining of DFT2 serial sections from six primary DFT2 tumours (Supplementary file 1) with these antibodies demonstrates expression of both classical (Saha-UA, -UB and –UC) and non-classical (Saha-UK) MHC class I molecules in vivo (Figure 3 and Figure 3—figure supplement 2). However, this analysis also demonstrates that MHC class I expression is variable in DFT2 tumours. Three of the tumours, DFT2_RVT1, DFT2_SNT2 and DFT2_818T1 (Figure 3), retain strong expression of classical class I molecules, with localisation to the cell membrane. This result is consistent with the cell surface expression of β2m observed on the DFT2_RV and DFT2_SN cell lines, derived from two of these primary tumours (Figure 1C and D). However, expression of classical MHC class I in DFT2_547 and DFT2_523 is weaker, appears mostly cytoplasmic and shows some variation in staining intensity, with some cells in DFT2_547 showing very low levels of expression. Strikingly, DFT2_812 is negative for classical MHC class I (Figure 3).

Figure 3. DFT2 tumours express variable levels of classical MHC class I (Saha-UA, -UB and -UC) and non-classical MHC class I (Saha-UK) in vivo.

IHC staining of DFT2 tumours (DFT2_RVT1, DFT2_SNT2, DFT2_818T1, DFT2_547T1, DFT2_523 DFT2_812) with α-UA/UB/UC_15-25-18 against Saha-UA, -UB and -UC and α-UK_15-29-1 against Saha-UK. Arrows indicate tumour cells for each biopsy; arrow heads indicate stroma separating nests of tumour cells where present. Isotype and secondary antibody controls can be found in Figure 3—figure supplement 2. Boxed insets are at 600 x magnification and are taken from areas indicated by arrows. Scale bars represent 50 μm. Positive cells for each marker are stained brown, nuclei are stained blue.

Figure 3—source data 1. Nucleotide sequences for the pET22B + SahaUC and pET22B + SahaUK constructs used to test the specificity of the MHC class I antibodies (a- UA/UB/UC 15-25-18 and a- UK 15-29-1) described in Figure 3.
elife-35314-fig3-data1.txt (2.1KB, txt)
DOI: 10.7554/eLife.35314.010

Figure 3.

Figure 3—figure supplement 1. Western blots illustrating specificity of the MHC class I heavy-chain monoclonal antibodies.

Figure 3—figure supplement 1.

Western blot on classical MHC class I protein (Saha-UC) (38 kDa) and non-classical MHC class I protein (Saha-UK) (39 kDa) with MHC class I heavy-chain specific antibodies.
Figure 3—figure supplement 2. Isotype controls (IgG1b – anti-SahaUA/UB/UC and IgG2b – anti-SahaUK) and secondary antibody only controls for the immunohistochemistry presented in Figure 3.

Figure 3—figure supplement 2.

All images are 100 x magnification with scale bars represent 100 μm.
Figure 3—figure supplement 3. DFT2 tumours have different growth patterns.

Figure 3—figure supplement 3.

H and E staining of four DFT2 tumours representing different growth patterns. Scale bars represent 100 μm.
Open in a new tab

The expression of Saha-UK also varies between and within DFT2 biopsies (Figure 3). DFT2_RVT1 cells are uniformly positive for Saha-UK, whereas DFT2_SNT2 and DFT2_547 have variable expression, with some areas staining more weakly. Interestingly, there is some evidence for Saha-UK staining in DFT2_812, a tumour negative for classical MHC class I, but DFT2_523 is largely Saha-UK negative (Figure 3). While the DFT2 tumours with strong classical class I expression show localisation to the cell membrane (i.e. cell surface expression), staining for Saha-UK shows a cytoplasmic distribution in some of the DFT2 tumours.

Notably, DFT2 tumours also show morphological heterogeneity (Figure 3—figure supplement 3). DFT2 tumour cells are sometimes arranged as nests separated by a fibroblastic stroma, for example DFT2_547T1, but can also be arranged in diffuse sheets separated by a fibrous component, for example DFT2_818T1 and DFT2_523T1. The degree of individual tumour cell nuclear pleomorphism can also vary within the same tumour (DFT2_SNT2).

DFT2 tumours can have infiltrating CD3 positive cells

The expression of MHC molecules by DFT2 cells may mean that this tumour is more immunogenic than DFT1. As infiltration of lymphocytes has been correlated with a positive prognostic outcome for some cancers (Galon et al., 2006; Chee et al., 2017) we stained DFT2 tumours for the lymphocyte marker, CD3. Staining of the primary tumours shows that lymphocyte infiltration does occur in some individuals (Figure 4). No CD3 positive cells were observed in DFT2_RV or DFT2_547 (Figure 4), but a more significant number of CD3 positive cells is evident in DFT2_818, DFT2_523 and DFT2_812 (Figure 4), where the lymphocytes are clustered at the stroma and some cells can be seen infiltrating the tumour mass. A small number of CD3 positive cells are visible in DFT2_SN (Figure 4).

Figure 4. CD3 staining of DFT2 tumours.

Figure 4.

Open in a new tab

CD3 staining of DFT2_RVT1, DFT2_SNT2 DFT2_818T1, DFT2_TD547T1, DFT2_523T2 and DFT2_812 tumours. CD3 positive cells are indicated by arrows. DFT2_SNT2, and DFT2_547 are CD3 negative. Scale bars represent 50 μm. Positive cells for each marker are stained brown, nuclei are stained blue.

DFT2 and DFT1 cells share MHC class I alleles

The classical MHC class I alleles expressed by DFT2 cells should play a role in any host immune response against the tumour. To assess the MHC class I alleles expressed by DFT2 cells we amplified, cloned and sequenced exon 2 (the region of the devil MHC class I where the majority of variation is located) of MHC class I transcripts from DFT2 cell lines. Previous analysis of DFT2 DNA has identified four MHC class I sequences from Saha-UA, Saha-UB and Saha-UC and one sequence from Saha-UD present in the DFT2 genome (Pye et al., 2016b). We find that DFT2 cells express all five genomic MHC class I sequences, SahaI*35 (Saha-UA), SahaI*90 (Saha-UB) SahaI*74/88 (unassigned), SahaI*27 (Saha-UC) and SahaI*32 (Saha-UD) loci (Table 1 and Figure 5). We also identified a sixth expressed sequence (SahaI*27–1) that differs from SahaI*27 by one non-synonymous substitution. Alignment of MHC class I sequences from DFT2 and DFT1 cells (when treated with IFNγ) show that across exon 2 of the heavy chain DFT1 and DFT2 share expression of four MHC class I alleles, SahaI*27, SahaI*90, SahaI*35 and SahaI*27–1, with only SahaI*46 unique to DFT1 and SahaI*74/88 unique to DFT2 (Table 1). Using gene specific primers we were able to confirm that both DFT2 and DFT1 cells also express Saha-UK (non-polymorphic) (Table 1 and Figure 2).

Table 1. MHC class I alleles expressed by DFT2 cell lines and host animals.

The classical and non-classical MHC class I alleles expressed by DFT1, DFT2, TD_RV, TD_818 and TD_SN. Grey boxes indicate the alleles identified in each sample. Numbers in the boxes indicate the number of clones identified for each allele. SahaI*32(UD) and SahaI*UK were amplified with gene specific primers.

Table 1–source data 1. MHC class I transcripts expressed in DFT2 and host devils that were used to generate Table 1 and Figure 5.
elife-35314-table1-data1.txt (6.9KB, txt)
DOI: 10.7554/eLife.35314.015
NCBI allele name DFT1 DFT2 TD_RV TD_818 TD_SN
SahaI*46
SahaI*27 22 22 14 2
SahaI*27–1 13 25 13
SahaI*74/88 9
SahaI*35 13 10
SahaI*90 4 1
SahaI*49/82 7
SahaI*97 6 2
SahaI*33 6 2
SahaI*36 2
SahaI*37 5 1
SahaI*29 2 2
SahaI*32(UD)
SahaI*UK
Open in a new tab

Figure 5. DFT2 shares classical MHC class I alleles with its hosts.

Alignment of the MHC class I sequences cloned from the mRNA from DFT2 cell lines (DFT2_CL) and host devils (TD_RV, TD_SN and TD_818 (Teu)). Nucleotide alignment in (A) and amino acid alignment in (B). Red asterisks indicate residues postulated to interact with peptides and blue asterisks indicate residues predicted to interact with TCRs (Bjorkman et al., 1987).

Figure 5.

Figure 5—figure supplement 1. Chromatograms of α2-domian of MHC class I from spleen samples from RV, SN and 818/Teu.

Figure 5—figure supplement 1.

Spln_RV, Spln_SN and Spln_818/Teu host tissues share the same polymorphic sites in the MHC class I α2-domian. Chromatograms of α2-domian of MHC class I (Saha-UA, -UB and –UC) from spleen samples from RV, SN and 818/Teu from PCR amplification and sequencing using the reverse primer Saha91. Polymorphic sites are indicated by an asterisk.
Open in a new tab

To assess the relative expression level of each of the classical MHC class I alleles in DFT2 cells, PCR amplicons were cloned and >60 clones were sequenced, resulting in 61 classical MHC class I sequences from DFT2. Of these sequences the most abundant is SahaI*27, representing 22 (36%) of the clones sequenced (Table 1). SahaI*27–1 and SahaI*35 were represented by 13 clones each (21%), while SahaI*74/88 and SahaI*90 were the least abundant, with 9 (15%) and 4 (6%) clones respectively. These results indicate that DFT2 cells do not express MHC class I alleles equally and that the dominant allele is SahaI*27.

DFT2 cells express high levels of a MHC class I allele common to its hosts

Given the dominant expression of SahaI*27 by DFT2 cells we determined the prevalence of SahaI*27 and other MHC class I alleles in three host devils. Exon 2 of MHC class I transcripts were amplified from the mRNA of spleen samples from three devils infected with DFT2 (TD_RV, TD_818 and TD_SN) (Table 1). Alignment of the sequences demonstrates that the host devils share SahaI*32 (Saha-UD), Saha-UK and SahaI*27 with DFT2. In addition, TD_818 and TD_SN share SahaI*27–1 and either SahaI*35 or SahaI*90 with DFT2 (Table 1 and Figure 5). The MHC class I alleles that are expressed by DFT2 cells but not by the hosts are of particular interest as they are likely to be immunogenic upon cell transmission. SahaI*74/88 is unique to the DFT2 cell lines and differs from SahaI*27 and SahaI*27–1 found in the host animals by a single non-synonymous substitution at position 59 or position 76, which are not predicted to interact with the TCR (Figure 5B). The class I alleles with lower expression on DFT2, SahaI*90 and SahaI*35, share between 91 and 97% amino acid identity with the host alleles.

To identify any further polymorphic sites that may have been missed when selecting clones for sequencing and to validate the sequences found in the hosts we used two approaches. First, we amplified and directly sequenced the MHC class I products from TD_RV, TD_818 and TD_SN to compare the chromatograms produced from sequencing pooled transcripts. This analysis did not reveal any additional polymorphic sites (Figure 5—figure supplement 1). Second, we used the sequences identified in Table 1 to conduct targeted searches of the genomes of TD_RV, TD_818 and TD_SN (Stammnitz et al., 2018) to confirm the presence of these alleles in genomic DNA.

Discussion

Here we show that DFT2 cells express classical and non-classical MHC class I molecules both in vitro and in vivo. This is in stark contrast to DFT1, a likely older and more widespread contagious cancer in the Tasmanian devil, which has lost expression of MHC class I (Siddle et al., 2013). However, DFT2 cells express the non-polymorphic, non-classical MHC class I molecule (Saha-UK) likely reducing the immunogenicity of these tumour cells. Further, the classical MHC class I allele with the highest expression in DFT2 cells is shared with host devils. Finally, we show that MHC class I expression varies among DFT2 tumours in vivo, suggesting that MHC class I negative subclones could emerge as DFT2 transmits more widely.

Our results demonstrate that DFT2 cells express MHC class I molecules, in contrast to DFT1 and the contagious cancer circulating among dogs, CTVT. DFT1 cells lack surface expression of MHC class I due to loss of β2m, TAP1 and TAP2 transcripts (Siddle et al., 2013). However, loss of MHC class I in DFT1 is reversible upon treatment with the inflammatory cytokine IFNγ (Siddle et al., 2013) and a small number of individuals have been found to have a successful immune response against the tumour (Pye et al., 2016a). Similarly, CTVT is thought to down-regulate MHC expression during transmission, but expression can be upregulated on CTVT cells during a tumour specific immune response from the host (Yang et al., 1987). In contrast, we show that DFT2 cells express cell surface β2m molecules in addition to classical and non-classical class I heavy chains, indicating that functional MHC class I are present on the surface of DFT2 cells.

The expression of a non-classical MHC class I molecule, Saha-UK, on DFT2 cells could reduce the immunogenicity of the tumour cells. Saha-UK is expressed in some DFT2 tumours in vivo and the Saha-UK heavy chain is expressed at similar levels to the three classical MHC class I genes (amplified as a group) in vitro. While antibodies specific for Saha-UD are not available, RT-PCR indicates it is also expressed, but at a very low level compared to Saha-UK. Non-classical MHC class I molecules can be inhibitory ligands for NK receptors and some human cancers down-regulate classical MHC class I and overexpress non-classical MHC class I to avoid a cytotoxic immune response (Kochan et al., 2013). While the function of Saha-UK and Saha-UD are not known (Siddle et al., 2009), neither are highly polymorphic (Saha-UK is monomorphic [Siddle et al., 2010]) and unlikely to elicit an allogeneic T cell response in host devils. However, further investigation is needed to determine the function of these molecules and the functional classification of Tasmanian devil MHC class I molecules as ‘classical’ or ‘non-classical’.

DFT2 cells also express classical MHC class I alleles belonging to the Saha-UA, -UB and -UC loci. Of these classical MHC class I alleles, SahaI*27 is the most abundant in DFT2 cells and is also found in the three host devils, reducing the immunogenicity of DFT2 cells in these animals. The primers designed in this study should amplify all known DFT1 and DFT2 MHC class I alleles with equal efficiency, suggesting that this allele represents an MHC class I locus with dominant expression. As well as being found in the host devils, this allele is highly prevalent in at least one devil population (Lane et al., 2012) and the high expression levels in DFT2 may be facilitating tolerance of the tumour in this population of devils. The similarity of the MHC class I alleles between DFT2 and host devils may reflect a shared geographical range and genotype pool to the cancer founder's (Stammnitz et al., 2018). Thus, the frequency of this allele among the wider population may impact the ability of DFT2 to spread further.

The heterogenic expression of MHC class I molecules in DFT2 biopsies suggests that MHC class I expression is not fixed and may be gradually lost in DFT2. While some MHC class I alleles are shared between DFT2 and its hosts, the tumour does have a number of unique alleles. SahaI*74/88 differs to SahaI*27 by only one amino acid that is not predicted to interact with the TCR, but SahaI*90 and SahaI*35 have a number of unique sites when compared to host MHC class I alleles. While these alleles have lower expression on DFT2 than SahaI*27, their presence may still initiate an immune response in some host animals, providing a selective pressure for MHC class I loss. It is possible that, like single organism tumours, DFT2 is undergoing immunoediting (Dunn et al., 2002), which can operate to down-regulate specific MHC class I alleles that are immunogenic (McGranahan et al., 2017) or select for mutations that remove or modulate total MHC class I expression. However, while four of the six primary DFT2 tumours examined have CD3 positive cells in the tumour mass, which may indicate an immune response, the infiltration is notably present in DFT2_812, which is negative for classical MHC class I and could be expected to be CD3 negative. Thus, further detailed analysis is needed to define the host immune response to DFT2 and its role in shaping tumour evolution.

While DFT1 cells currently circulating in the population are MHC class I negative, it is possible that DFT1 down regulated MHC class I expression after the tumour became transmissible and that initial transmission events were among individuals that shared prevalent MHC class I alleles. This is supported by previous studies that have found reduced polymorphism in devil MHC and microsatellite loci (Jones et al., 2007; Siddle et al., 2007). In addition, a hemizygous deletion of β2m has recently been identified in a DFT1 cell line, perhaps indicating past selective pressure for MHC class I loss in this older transmissible tumour (Stammnitz et al., 2018). Similarly, CTVT is thought to have emerged in an old world dog and the genetic structure of a dog pack would have favoured the emergence of CTVT (Murgia et al., 2006). However, the presence or absence of MHC antigens is likely not singly responsible for determining the ability of the host to respond to the tumour. DFT2 may also be manipulating its microenvironment by release of immune suppressive cytokines, such as Transforming Growth Factorβ, which can drive metastasis (Tauriello et al., 2018) and in conjunction with PD1/PD-L1 interactions can inhibit and exclude T cells from a tumour (Mariathasan et al., 2018). In addition, recruitment of T regulatory cells (Curiel et al., 2004; James et al., 2010) or immunosuppressive myeloid cells (Almand et al., 2001) can also negatively impact the T cell responses to tumours.

DFT1 is now at least 21 years old and CTVT is predicted to be over 10,000 years old (Murchison et al., 2014), whereas DFT2 was first discovered in 2014 and is most likely a recently emerged tumour (Pye et al., 2016b). As such, DFT2 provides an opportunity to study the early evolution of a contagious cancer. The emergence of a contagious cancer that can transmit while maintaining MHC class I expression indicates that loss of MHC is not necessary for transmission, but as the tumour encounters the immune system of genetically disparate hosts subclones that have down-regulated MHC may be selected. Our results predict that loss of MHC class I is already occurring, perhaps due to structural mutations or epigenetic changes. Loss of MHC antigens could allow rapid dissemination of DFT2 through the population, impacting an already vulnerable species.

Materials and methods

Key resources table.

Reagent type (species)
or resource		 Designation Source or reference Identifiers Additional information
Gene
(Sarcophilus harrisii)		 Saha-UK Murchison et al. (2012) ensembl:
ENSSHAG00000002942		 Devil_ref v7.0
Gene (S. harrisii) Saha-UC Murchison et al. (2012) ensembl:
ENSSHAG00000000117		 Devil_ref v7.0
Gene (S. harrisii) Saha-UD Murchison et al. (2012) ensembl:
ENSSHAG00000010776		 Devil_ref v7.0
Cell line (S. harrisii) DFT1_4906 Siddle et al. (2013) and
Murchison et al. (2012) 		RRID:CVCL_LB78;
DFTD 4906; 86T		 Devil Facial Tumour 1;
Supplementary file 1
Cell line (S. harrisii) DFT2_RV Pye et al. (2016b) DFT2_202T1 Devil Facial Tumour 2;
Supplementary file 1
Cell line (S. harrisii) DFT2_SN Pye et al. (2016b) DFT2_203T3 Devil Facial Tumour 2;
Supplementary file 1
Cell line (S. harrisii) DFT2_549 This paper Devil Facial Tumour 2;
Supplementary file 1
Cell line
(S. harrisii) (Female)		 Fibroblasts_Salem Murchison et al. (2012) 91 H Tasmanian devil fibroblasts
Cell line
(Cricetulus griseus)		 CHO_SahaIFNy Siddle et al. (2013) Chinese Hamster Ovary (CHO)
cell line transfected with
pcDNA3_SahaIFNy
Biological sample
(S. harrisii)		 DFT2_RV Pye et al. (2016b) DFT2_202T1 Devil Facial Tumour 2;
Supplementary file 1
Biological sample
(S. harrisii)		 DFT2_SN Pye et al. (2016b) DFT2_203T2 Devil Facial Tumour 2;
Supplementary file 1
Biological sample
(S. harrisii)		 DFT2_818 Stammnitz et al. (2018) Devil Facial Tumour 2;
Supplementary file 1
Biological sample
(S. harrisii)		 DFT2_547 Stammnitz et al. (2018) 807T1 Devil Facial Tumour 2;
Supplementary file 1
Biological sample
(S. harrisii)		 DFT2_523 Stammnitz et al. (2018) 638T1 Devil Facial Tumour 2;
Supplementary file 1
Biological sample
(S. harrisii)		 DFT2_812 Stammnitz et al. (2018) Devil Facial Tumour 2;
Supplementary file 1
Biological sample
(S. harrisii)		 TD_RV Stammnitz et al. (2018) 202H1 Tasmanian devil spleen
biopsy
Biological sample
(S. harrisii)		 TD_SN Stammnitz et al. (2018) 203 H Tasmanian devil kidney
biopsy
Biological sample
(S. harrisii)		 TD_818 Stammnitz et al. (2018) 818 Tasmanian deil spleen
biopsy
Antibody α-UA/UB/UC_15-25-18;
Classical MHC class I Saha-UA,
-UB and -UC		 This paper UA/UB/UC_15-25-18 Antibody recognising MHC
class I molecules,SahaUA,
UB and UC. Generated using
a peptide immunogen
(WMEKVQDVDPGYWE).
Supernatant from hybridoma
used neat.
Antibody α-UK_15-29-1; Non-classical
MHC class I Saha-UK		 This paper α-UK_15-29-1 Antibody recognising MHC
class I molecule,Saha-UK.
Generated using a peptide
immunogen (RITHRTHPDGKVTL).
Supernatant from hybridoma
used neat.
Antibody IgG1 Isotype control Sigma Aldrich clone: MOPC-21;
cat number: M5284		 0.5 mg/ml
Antibody IgG2b Isotype control Sigma Aldrich clone: MOPC-141;
cat number: M5534		 0.5 mg/ml
Antibody a-B2m Siddle et al. (2013) SahaB2m-13-34-48 supernatant used neat;
B2-microglogulin
Antibody a-CD3 Dako/Agilent cat number: A0452 1:50
Recombinant DNA
reagent		 pET22B+-SahaUC This paper SahaI*UC (SahaI*27) amplified
using primer Saha349 and Saha350
(Supplementary file 2).
Recombinant DNA
reagent		 pET22B+-SahaUK This paper Saha-UK in Pet22B + using primer
Saha335 and Saha351
(Supplementary file 2).
Open in a new tab

Animals

Six wild Tasmanian devils were either trapped or found dead from road trauma or other causes. Tissue biopsies and fine needle aspirates were either collected post mortem or from live devils that were subsequently released. All animal procedures were performed under a Standard Operating Procedure approved by the General Manager, Natural and Cultural Heritage Division, Tasmanian Government Department of Primary Industries, Parks, Water and the Environment or under University of Tasmania Animal Ethics Committee Permit A0014976. Sample information is shown in Supplementary file 1. Tumour and spleen samples were collected as described in Supplementary file 1 and were formalin fixed (10% neutral buffered formalin) and then paraffin embedded.

Cell culture conditions and IFNγ treatment

The DFT1 cell line, DFT1_4906, and fibroblast cell line, Fibroblasts_Salem, have been described elsewhere (Murchison et al., 2012). Three cell lines derived from DFT2 primary tumours (DFT2_RV, DFT2_SN and DFT2_TD549) were established from fine needle aspirates collected in culture medium and cultured at 35°C and 5% CO2. Cell lines DFT1_4906, DFT2_RV and DFT2_SN were grown in RPMI 1640 with L-glutamine (Gibco; ThermoFisher Scientific) with 10% heat inactivated foetal bovine serum (FBS) (Gibco; ThermoFisher Scientific) and penicillin/streptomycin (100 units/ml penicillin and 0.1 mg/ml streptomycin) (Gibco; ThermoFisher Scientific). Fibroblasts_Salem was cultured in DMEM with high glucose and L-glutamine (Gibco; ThermoFisher Scientific) with 10% FBS (Gibco; ThermoFisher Scientific) and penicillin/streptomycin (100 units/ml penicillin and 0.1 mg/ml streptomycin) (Gibco; ThermoFisher Scientific). Cells were passaged at 80–90% confluency at a ratio of 1:3 using trypsin (0.05%) to detach cells. DFT1 cells were treated with recombinant devil IFNγ derived from a transfected cell line (CHO_SahaIFNy) as previously described (Siddle et al., 2013).

Flow cytometry

Cells were incubated on ice with anti-devil β2m antibody supernatant for 30 min, followed by secondary antibody (2 μg/ml goat anti-Mouse IgG (H + L) Alexa Fluor 488 Conjugate; ThermoFisher Scientific) for 30 min. The specificity of the antibody was confirmed by incubating 50 μg/ml recombinant devil β2m protein (Siddle et al., 2013) with anti-devil β2m antibody on ice for 30 min prior to staining. Cells were analysed on BD FACSCalibur and data analysed using FlowJo software.

Development of anti-Saha-UK and anti-Saha-UA-UB-UC antibodies

MHC class I transcripts were aligned and translated into protein sequences using CLC workbench. Two regions were identified, in the α1 domain and the α3 domain, where the amino acid sequenced of the Saha-UA, -UB and –UC sequences are highly similar to each other, with only one amino acid change, but contain low similarity to Saha-UK and Saha-UD. Using these sequences the following peptides were synthesised for immunisations, WMEKVQDVDPGYWE against Saha-UA, -UB and -UC and RITHRTHPDGKVTL against Saha-UK. Mice were immunised subcutaneously with a mixture of GERBU adjuvant and 50 μg of either WMEKVQDVDPGYWE-C or RITHRTHPDGKVTL-C coupled to diphtheria toxoid via the N-terminal cysteine. Three days later spleen lymphocytes were fused with the SP2 cell line using PEG as fuseogen. Hybridomas were selected based on reactivity in ELISA against both N- and C-terminal coupled peptide and subsequently screened against Tasmanian devil fibroblast cells and verified against recombinant expressed MHC class I by western blot as described below.

Electrophoresis and western blotting for antibody screening

Cell pellets were lysed on ice for 30 min at 4 × 107 cells/ml lysis buffer (150 mM NaCl, 100 mM TrisCl, 1 mM MgCL2 and 1% digitonin) and the lysates clarified. 10 μl of cell lysate was added to 15 μl loading buffer (500 μl 2X Lamelli sample buffer, 50 μl β-mercaptoethanol and 450 μl dd-H2O) and heated to 95°C 10 min. Samples were run on 12% ProtoGel (National Diagnostics Protogel 30%) using Laemmli buffers and Fisherbrand Vertical Gel Tank. Proteins were transferred to nitrocellulose blotting membrane (Amersham Protran GE Healthcare Life Sciences) in transfer buffer (25 mM Tris, 190 mM glycine and 20% (w/v) methanol) using Mini Trans-Blot Cell (Bio-Rad). The membrane was blocked for 45 min with 150 mM NaCl, 0.1% Tween 20, 4% milk powder, 50 mM TrisCL, pH 8 and incubated with primary antibodies at 4°C overnight, washed with 150 mM NaCl, 0.1% Tween 20, 4% milk powder, 50 mM TrisCL, pH 8, and incubated with secondary antibody (IRDye 680RD Goat anti-Mouse IgG (H + L)) for 30 min at room temperature before washing as above. Membranes were visualised using the Li-cor Odyssey scanner.

Specificity of classical MHC class I (Saha-UA, -UB and -UC) and non-classical MHC class I (Saha-UK) antibodies

The specificity of the antibodies was determined using full length recombinant devil MHC class I heavy chain proteins for Saha-UC (SahaI*27) and Saha-UK. SahaI*27 and Saha-UK were amplified from devil fibroblast cDNA using primer Saha349 and Saha350 (Saha-UC) and Saha335 and Saha351 (Saha-UK) (Supplementary file 2). The subsequent amplicons were cloned into the pET22b+ vector (Novagen) and transformed into Rosetta pLysS cells (Novagen) according to the manufacturer’s instructions and the transcripts were sequenced in both directions. Bacterial colonies containing pET22B+-SahaUC and pET22B+-SahaUK were cultured to OD600 0.6 and protein expression was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). Bacterial cells were pelleted and resuspended in solubilisation buffer (8 M Urea, 50 mM Mes pH 6.5, 0.1 mM EDTA and 1 mM DTT) and the lysates clarified. The total protein in lysates was measured using Bradford Reagent following the manufacturers instructions. 20 μg protein was loaded onto a 12% gel and electrophoresis and blotting were performed as described above. Membranes were incubated with the undiluted supernatant from primary antibodies α-UK_15-29-1 and α-UA/UB/UC_15-25-18 at 4°C overnight.

Immunohistochemistry

DFT1 and DFT2 primary tumours were fixed in 10% (mass/vol) PBS-buffered formalin solution for 2 to 4 d. Tissues were processed and embedded in paraffin blocks and cut onto coated slides at 4–5 μm thickness. Sections were deparaffinized in xylene and rehydrated through graded alcohol. Antigen retrieval was performed by water bath (95°C) in citrate buffer solution (10 mM citric acid, 0.05% Tween20 pH 6) for 40 min followed by cooling for 15 min. Endogenous peroxidase was blocked by incubation of slides with 0.3% H2O2 (Sigma Aldrich) and non-specific protein binding was blocked with 10% (mass/vol) goat serum. Sections were incubated with primary antibody (list of antibodies in Supplementary file 3) at 4°C overnight. Peroxidase-coupled secondary antibody (Envision kit; Dako) was used to detect primary antibody binding following the manufacturers instructions. Sections were counterstained with haematoxylin (vector hematoxylin nuclear counterstain Gill’s Formula) for 4 min, differentiated in 2% (mass/vol) acetic acid and blued in 0.2% (mass/vol) ammoniated water. Sections were dehydrated through graded alcohol to xylene and cover-slipped. Images were captured using the Nikon Eclipse 400 microscope, Retiga 2000R camera and Q-capture pro seven computer software.

RT-qPCR

The Nucleospin RNA II kit (Macherey-Nagel) was used to extract RNA from cell lines according to the manufacturer’s instructions. 1 μg of RNA was reverse transcribed to cDNA using Thermofischer Scientific RevertAid Premium Reverse Transcriptase (200 U) with 1X RT buffer, 0.5 mM dNTPs, 20 pm oligodT primer (Promega) and nuclease free H2O to a total volume of 20 μl. Primer set one was designed to amplify the classical MHC class I (Saha-UA, -UB and –UC) by aligning all available MHC class I sequences from the Tasmanian devil and embedding primers in conserved regions. Primer set one amplifies the three loci as a group, due to the high level of sequence similarity between the classical class I genes, gene specific PCRs for these loci were not possible. Primer set two was designed to amplify the non-classical MHC class I (Saha-UK). All primers are listed in Supplementary file 2. RT-qPCR was carried out for RPL13A, β2m, classical MHC class I (Saha-UA, -UB and -UC) and non-classical MHC class I (Saha-UK) on the StepOnePlus Real-Time PCR system (ThermoFisher Scientific) using PrecisionPLUS qPCR MasterMix (Primerdesign) with primers at 5 mM each following the cycling protocol; 95°C 2 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. RPL13A was used as the reference gene and data analysis was performed using the relative standard curve method for comparing gene expression (DFT1_4906 = 1). All cDNA samples were tested in triplicate and controls with no cDNA template were included. DFT2 at four dilutions (250, 50, 10, 2 and 0.4 ng) was used to create a standard curve of amplification for RPL13A with an R2 of 0.999 and 97.14% efficiency. Recombinant DNA at five dilutions (0.2, 0.04, 0.008, 0.00016 and 0.000032) was used to create a standard curve of amplification of MHC class I Saha-UK and MHC class I Saha-UA, UB and UC with R2 values of 0.991 and 0.997% and 105.2 and 111.4% efficiency respectively. IFNγ treated DFT1 (4906) cells at five dilutions (250, 50, 10, 2 and 0.4 ng) was used to create a standard curve of amplification for β2m with an R2 of 0.994 and 91.4% efficiency.

RT-PCR and sequencing of MHC class I transcripts in DFT2, DFT1 and host devils

The Nucleospin RNA II kit (Macherey-Nagel) was used to extract RNA from DFT2 cell lines, DFT1 cells after treatment with IFNγ, and host samples (TD_RV, TD_SN and TD_818). The NucleoSpin totalRNA FFPE kit (Macherey-Nagel) was used to extract RNA from formalin fixed tumour tissues according to the manufacturer’s instructions. 1 μg of RNA was reverse transcribed to cDNA as described previously. Three primer sets were used to amplify all classical and non-classical MHC class I alleles. Primer set one was used to amplify Saha-UA, -UB and –UC products as a group, primer sets 2 and 3 were used to amplify Saha-UK and Saha-UD genes specifically (for PCR conditions see Supplementary file 4). All products were purified using NucleoSpin Gel and PCR Clean-up (Macherey-Nagel), cloned into a pJET plasmid (CloneJET; ThermoFisher Scientific). Plasmid DNA from individual clones was isolated and sequenced using T7 primer. PCR, cloning and sequencing was performed in triplicate for the DFT2 cells and duplicate for the spleen samples. For primer set 1 between 15 and 65 clones were sequenced for each PCR, for primer sets 2 and 3 between 4 and 6 clones were sequenced. To assess the relative abundance of each of the classical MHC class I alleles within DFT2 cells 65 clones were isolated and sequenced using primer set 1.

To validate the MHC class I alleles, Saha-UA, -UB and -UC genes were amplified using primer set one as described above and resulting PCR products (containing all MHC class I alleles for these genes) were sequenced directly using these primers. The resulting chromatograms were used to identify polymorphic sites in the transcripts and to confirm the validity of alleles. In addition, MHC class I alleles for RV, 818 and SN were searched against genomes generated for these animals (Stammnitz et al., 2018) to validate their presence in the genome. All sequences were quality checked and analysed in CLC Genomic Workbench. Residues in the MHC class I sequences predicted to interact with the peptide or the TCR were identified by aligning to HLA-A2 (Bjorkman et al., 1987).

Acknowledgements

The authors thank the histology department at the University of Southampton Hospital for H and E staining and paraffin embedding some tumour samples. This work was supported by a Research Project Grant from Leverhulme Trust (RPG-2015–103) to HVS and TE. AC is supported by the Gerald Kerkut Charitable Trust and University of Southampton Vice-Chancellor’s scholarship. EPM, MRS and YMK are supported by the Wellcome Trust (102942/Z/13/A) and a Philip Leverhulme Prize awarded by the Leverhulme Trust. MRS is supported by a scholarship from the Gates Cambridge Trust and YMK is supported by a Herchel Smith Postgraduate Scholarship.

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Contributor Information

Hannah VT Siddle, Email: H.V.Siddle@soton.ac.uk.

Arup K Chakraborty, Massachusetts Institute of Technology, United States.

Ronald N Germain, National Institute of Allergy and Infectious Diseases, United States.

Funding Information

This paper was supported by the following grants:

  • Gerald Kerkut Charitable Trust Postgraduate student scholarship to Alison Caldwell.

  • University of Southampton Vice-Chancellor's Scholarship to Alison Caldwell.

  • Gates Cambridge Trust to Maximilian R Stammnitz.

  • Wellcome 102942/Z/13/A to Elizabeth P Murchison, Maximilian R Stammnitz, Young Mi Kwon.

  • Leverhulme Trust Philip Leverhulme Prize to Elizabeth P Murchison, Maximilian R Stammnitz, Young Mi Kwon.

  • Leverhulme Trust RPG-2015-103 to Tim Elliott, Hannah VT Siddle.

  • Herchel Smith Postgraduate Scholarship to Young Mi Kwon.

Additional information

Competing interests

No competing interests declared.

Author contributions

Formal analysis, Investigation, Writing—original draft.

Investigation.

Investigation.

Resources, Validation, Methodology.

Validation.

Investigation, Writing—review and editing.

Investigation.

Resources, Validation, Writing—review and editing.

Resources, Supervision, Writing—review and editing.

Formal analysis, Investigation.

Resources, Investigation, Writing—review and editing.

Conceptualization, Supervision, Writing—review and editing.

Resources, Investigation, Writing—review and editing.

Conceptualization, Supervision, Funding acquisition, Investigation, Writing—original draft, Writing—review and editing.

Ethics

Animal experimentation: All animal procedures were performed under a Standard Operating Procedure approved by the General Manager, Natural and Cultural Heritage Division, Tasmanian Government Department of Primary Industries, Parks, Water and the Environment or under University of Tasmania Animal Ethics Committee Permit A0014976.

Additional files

Supplementary file 1. Biological samples used in this study.

Details of the tumour and host tissue samples, the date the samples were collected from the animal and the location of the animal when it was trapped. *As described previously (Pye et al., 2016b).

elife-35314-supp1.docx (13.1KB, docx)
DOI: 10.7554/eLife.35314.016
Supplementary file 2. Primers used in this study with amplicon size and optimised annealing temperature.
elife-35314-supp2.docx (13.9KB, docx)
DOI: 10.7554/eLife.35314.017
Supplementary file 3. Antibodies used in this study.
elife-35314-supp3.docx (12.5KB, docx)
DOI: 10.7554/eLife.35314.018
Supplementary file 4. PCR conditions for the primers used in this study.
elife-35314-supp4.docx (13.4KB, docx)
DOI: 10.7554/eLife.35314.019
Transparent reporting form
elife-35314-transrepform.docx (246.5KB, docx)
DOI: 10.7554/eLife.35314.020

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Table 1, Figure 5 and Figure 3-figure supplement 1.

The following previously published datasets were used:

Murchison, author. Devil_ref v7.0 (GCA_000189315.1) 2012 http://www.ensembl.org/Sarcophilus_harrisii/Info/Index Publicly available at the European Nucleotide Archive (accession no: GCA_000189315.1)

Stammnitz, author. Genomes of Tasmanian devil transmissible cancers DFT1, DFT2 and normal animals. 2018 https://www.ebi.ac.uk/ena/data/view/PRJEB21902 Publicly available at the European Nucleotide Archive (accession no: ENA: PRJEB21902)

References

  1. Adams EJ, Parham P. Species-specific evolution of MHC class I genes in the higher primates. Immunological Reviews. 2001;183:41–64. doi: 10.1034/j.1600-065x.2001.1830104.x. [DOI] [PubMed] [Google Scholar]
  2. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. The Journal of Immunology. 2001;166:678–689. doi: 10.4049/jimmunol.166.1.678. [DOI] [PubMed] [Google Scholar]
  3. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987;329:506–512. doi: 10.1038/329506a0. [DOI] [PubMed] [Google Scholar]
  4. Braud VM, Allan DS, McMichael AJ. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Current Opinion in Immunology. 1999;11:100–108. doi: 10.1016/S0952-7915(99)80018-1. [DOI] [PubMed] [Google Scholar]
  5. Chee SJ, Lopez M, Mellows T, Gankande S, Moutasim KA, Harris S, Clarke J, Vijayanand P, Thomas GJ, Ottensmeier CH. Evaluating the effect of immune cells on the outcome of patients with mesothelioma. British Journal of Cancer. 2017;117:1341–1348. doi: 10.1038/bjc.2017.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cheng Y, Belov K. Characterisation of non-classical MHC class I genes in the Tasmanian devil (Sarcophilus harrisii) Immunogenetics. 2014;66:727–735. doi: 10.1007/s00251-014-0804-3. [DOI] [PubMed] [Google Scholar]
  7. Cheng Y, Stuart A, Morris K, Taylor R, Siddle H, Deakin J, Jones M, Amemiya CT, Belov K. Antigen-presenting genes and genomic copy number variations in the Tasmanian devil MHC. BMC Genomics. 2012;13:87. doi: 10.1186/1471-2164-13-87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine. 2004;10:942–949. doi: 10.1038/nm1093. [DOI] [PubMed] [Google Scholar]
  9. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology. 2002;3:991–998. doi: 10.1038/ni1102-991. [DOI] [PubMed] [Google Scholar]
  10. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi: 10.1126/science.1129139. [DOI] [PubMed] [Google Scholar]
  11. Hamede RK, Pearse AM, Swift K, Barmuta LA, Murchison EP, Jones ME. Transmissible cancer in Tasmanian devils: localized lineage replacement and host population response. Proceedings of the Royal Society B: Biological Sciences. 2015;282:20151468. doi: 10.1098/rspb.2015.1468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hawkins CE, Baars C, Hesterman H, Hocking GJ, Jones ME, Lazenby B, Mann D, Mooney N, Pemberton D, Pyecroft S, Restani M, Wiersma J. Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii. Biological Conservation. 2006;131:307–324. doi: 10.1016/j.biocon.2006.04.010. [DOI] [Google Scholar]
  13. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Molecular Medicine Today. 1999;5:178–186. doi: 10.1016/S1357-4310(99)01451-3. [DOI] [PubMed] [Google Scholar]
  14. Hsiao YW, Liao KW, Hung SW, Chu RM. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Veterinary Immunology and Immunopathology. 2002;87:19–27. doi: 10.1016/S0165-2427(02)00026-0. [DOI] [PubMed] [Google Scholar]
  15. James E, Yeh A, King C, Korangy F, Bailey I, Boulanger DS, Van den Eynde BJ, Murray N, Elliott TJ. Differential suppression of tumor-specific CD8+ T cells by regulatory T cells. The Journal of Immunology. 2010;185:5048–5055. doi: 10.4049/jimmunol.1000134. [DOI] [PubMed] [Google Scholar]
  16. Jones ME, Jarman PJ, Lees CM, Hesterman H, Hamede RK, Mooney NJ, Mann D, Pukk CE, Bergfeld J, McCallum H. Conservation management of Tasmanian devils in the context of an emerging, Extinction-threatening disease: devil facial tumor disease. EcoHealth. 2007;4:326–337. doi: 10.1007/s10393-007-0120-6. [DOI] [Google Scholar]
  17. Kochan G, Escors D, Breckpot K, Guerrero-Setas D. Role of non-classical MHC class I molecules in cancer immunosuppression. OncoImmunology. 2013;2:e26491–26498. doi: 10.4161/onci.26491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kwon Y, Stammnitz MR, Wang J, Knowles GW, Pye RJ, Hamede R, Murchison EP. Tasman-PCR: a genetic diagnostic assay for Tasmanian Devil facial tumour diseases. bioRxiv. 2018 doi: 10.1101/287847. [DOI] [PMC free article] [PubMed]
  19. Lane A, Cheng Y, Wright B, Hamede R, Levan L, Jones M, Ujvari B, Belov K. New insights into the role of MHC diversity in Devil facial tumour disease. PLoS One. 2012;7:e36955–36959. doi: 10.1371/journal.pone.0036955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, Şenbabaoğlu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, Höglund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T. Tgfβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–548. doi: 10.1038/nature25501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C, TRACERx Consortium Allele-Specific HLA loss and immune escape in lung Cancer evolution. Cell. 2017;171:1259–1271. doi: 10.1016/j.cell.2017.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Metzger MJ, Reinisch C, Sherry J, Goff SP. Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams. Cell. 2015;161:255–263. doi: 10.1016/j.cell.2015.02.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Metzger MJ, Villalba A, Carballal MJ, Iglesias D, Sherry J, Reinisch C, Muttray AF, Baldwin SA, Goff SP. Widespread transmission of independent cancer lineages within multiple bivalve species. Nature. 2016;534:705–709. doi: 10.1038/nature18599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ, Fu B, Hims M, Ding Z, Ivakhno S, Stewart C, Ng BL, Wong W, Aken B, White S, Alsop A, Becq J, Bignell GR, Cheetham RK, Cheng W, Connor TR, Cox AJ, Feng ZP, Gu Y, Grocock RJ, Harris SR, Khrebtukova I, Kingsbury Z, Kowarsky M, Kreiss A, Luo S, Marshall J, McBride DJ, Murray L, Pearse AM, Raine K, Rasolonjatovo I, Shaw R, Tedder P, Tregidgo C, Vilella AJ, Wedge DC, Woods GM, Gormley N, Humphray S, Schroth G, Smith G, Hall K, Searle SM, Carter NP, Papenfuss AT, Futreal PA, Campbell PJ, Yang F, Bentley DR, Evers DJ, Stratton MR. Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell. 2012;148:780–791. doi: 10.1016/j.cell.2011.11.065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Murchison EP, Wedge DC, Alexandrov LB, Fu B, Martincorena I, Ning Z, Tubio JMC, Werner EI, Allen J, De Nardi AB, Donelan EM, Marino G, Fassati A, Campbell PJ, Yang F, Burt A, Weiss RA, Stratton MR. Transmissible [corrected] dog cancer genome reveals the origin and history of an ancient cell lineage. Science. 2014;343:437–440. doi: 10.1126/science.1247167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA. Clonal origin and evolution of a transmissible cancer. Cell. 2006;126:477–487. doi: 10.1016/j.cell.2006.05.051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Novinski MA. Zur frage uber die impfung der krebsigen geschwulste. Zentralbl Med Wissensch. 1876;14:790–791. [Google Scholar]
  28. Pearse AM, Swift K. Transmission of devil facial-tumour disease. Nature. 2006;439:549. doi: 10.1038/439549a. [DOI] [PubMed] [Google Scholar]
  29. Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, Kreiss A, Jones ME, Lyons AB, Woods GM. Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils. Biology Letters. 2016a;12:20160553. doi: 10.1098/rsbl.2016.0553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pye RJ, Pemberton D, Tovar C, Tubio JM, Dun KA, Fox S, Darby J, Hayes D, Knowles GW, Kreiss A, Siddle HV, Swift K, Lyons AB, Murchison EP, Woods GM. A second transmissible cancer in Tasmanian devils. PNAS. 2016b;113:374–379. doi: 10.1073/pnas.1519691113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pérez J, Day MJ, Mozos E. Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumour at different stages of growth. Veterinary Immunology and Immunopathology. 1998;64:133–147. doi: 10.1016/S0165-2427(98)00131-7. [DOI] [PubMed] [Google Scholar]
  32. Rosenberg AS. The T cell populations mediating rejection of MHC class I disparate skin grafts in mice. Transplant Immunology. 1993;1:93–99. [PubMed] [Google Scholar]
  33. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annual Review of Immunology. 1993;11:385–402. doi: 10.1146/annurev.iy.11.040193.002125. [DOI] [PubMed] [Google Scholar]
  34. Siddle HV, Deakin JE, Coggill P, Hart E, Cheng Y, Wong ES, Harrow J, Beck S, Belov K. MHC-linked and un-linked class I genes in the wallaby. BMC Genomics. 2009;10:310. doi: 10.1186/1471-2164-10-310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Siddle HV, Kreiss A, Eldridge MDB, Noonan E, Clarke CJ, Pyecroft S, Woods GM, Belov K. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. PNAS. 2007;104:16221–16226. doi: 10.1073/pnas.0704580104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng Y, Belov K, Swift K, Pearse AM, Hamede R, Jones ME, Skjødt K, Woods GM, Kaufman J. Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. PNAS. 2013;110:5103–5108. doi: 10.1073/pnas.1219920110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Siddle HV, Marzec J, Cheng Y, Jones M, Belov K. MHC gene copy number variation in Tasmanian devils: implications for the spread of a contagious cancer. Proceedings of the Royal Society B: Biological Sciences. 2010;277:2001–2006. doi: 10.1098/rspb.2009.2362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Stammnitz MR, Coorens THH, Gori KC, Hayes D, Fu B, Wang J, Martin-Herranz DE, Alexandrov LB, Baez-Ortega A, Barthorpe S, Beck A, Giordano F, Knowles GW, Kwon YM, Hall G, Price S, Pye RJ, Tubio JMC, Siddle HVT, Sohal SS, Woods GM, McDermott U, Yang F, Garnett MJ, Ning Z, Murchison EP. The origins and vulnerabilities of two transmissible cancers in Tasmanian devils. Cancer Cell. 2018;33:607–619. doi: 10.1016/j.ccell.2018.03.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, Byrom D, Matarin JA, Calon A, Rivas EI, Nebreda AR, Riera A, Attolini CS, Batlle E. Tgfβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–543. doi: 10.1038/nature25492. [DOI] [PubMed] [Google Scholar]
  40. Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, Darby J, Malley RC, Siddle HV, Skjødt K, Kaufman J, Silva A, Baz Morelli A, Papenfuss AT, Corcoran LM, Murphy JM, Pearse MJ, Belov K, Lyons AB, Woods GM. Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. Scientific Reports. 2017;7:43827. doi: 10.1038/srep43827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Yang TJ, Chandler JP, Dunne-Anway S. Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma. British Journal of Cancer. 1987;55:131–134. doi: 10.1038/bjc.1987.27. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision letter

Editor: Ronald N Germain1
Reviewed by: Mel Greaves2

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article "The newly-arisen Devil Facial Tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer" for consideration by eLife. Your article has been reviewed by Arup Chakraborty as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Mel Greaves (Reviewer #1); Rob Miller (Reviewer #2); Cornelis Melief (Reviewer #3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

While all the referees found the subject of interest and the findings of relevance to understanding immune – tumor interactions, they also found limitations to the study in its current state. The major areas of concern involved the immunohistochemical findings as well as some of the conclusions that were reached without sufficient corresponding data.

Essential Revisions:

1) Detailed and specific PCR-based analysis of MHC locus expression in DFT2 cells was carried out on cell lines (#3). In vivo analysis was more limited and based on antibody screening (and revealed variable cell-cell expression). Are the cell lines representative of the in vivo tumor? If MHC down-regulation in vivo is epigenetic, then expression in vitro could be misleading. The paper would be substantially strengthened if it is possible to provide some validation of the cell line data using tissue samples. In this regard, patchiness of the immunohistochemical staining seems odd. Why should there be areas of continued expression and areas where there is loss of expression? Why wouldn't loss of expression be more random? Some of the images seem to show that staining is peripheral in to the tumors (Figure 4—figure supplement 1). Was this the case and why might that be? Because the older sections of the tumor were more likely to have lost expression? Were sequential sections stained with anti-UA, B, C followed by anti-UK to see if staining is common to areas and therefore may be artifact or some evidence of co-staining?

2) It is unclear how the authors think it likely DFT2 succeeds in immune evasion. Is it (a) there is nothing to be recognised on DFT2 cells; or (b) the DFT2 cells are immune-suppressive? The suggestion that non-classical MHC class 1 molecules (Saha) are inhibitory appears to be entirely speculative. Can the authors provide further studies that might illuminate the mechanism?

In this regard, MHC molecule expression in vivo is recorded as variable. From this the authors conclude that they may be catching immune-editing or evolutionary selection for MHC loss as it happens. This could be true, but it is unpersuasive and very speculative; there is considerable variation in expression and no evidence for emerging dominance of MHC negative variants. Importantly, the authors do not observe infiltration of tumor with lymphocytes which might reflect ongoing selection. How do they reconcile this with their hypothesis about immune evasion and selection? One would expect processing and presentation in the MHC I molecules of minor histocompatibility antigens, at least some of which are expected to differ between the first animal from whom the tumor arose and subsequent recipients. Therefore, other reasons such as a T cell hostile micro-environment despite the presence of minor H differences may play a role in the selection for transmission of the cancer. This could include a variety of mechanisms also reported for immunogenic cancers in autologous hosts:

1) Exclusion of T cells by TGFβ (two recent Nature papers)

2) High numbers of immunosuppressive myeloid cells

3) Lack of the proper chemokines and/ or chemokine receptors

4) Hypoxia

5) IDO expression

The authors are encouraged to discuss this and refer to relevant review papers cataloguing these possibilities for autochthonous tumors. If this is researched further, it may lead to therapeutic possibilities that are also relevant for immunotherapy of cancer in general.

eLife. 2018 Aug 14;7:e35314. doi: 10.7554/eLife.35314.027

Author response

Essential Revisions:

1) Detailed and specific PCR-based analysis of MHC locus expression in DFT2 cells was carried out on cell lines (#3). In vivo analysis was more limited and based on antibody screening (and revealed variable cell-cell expression). Are the cell lines representative of the in vivo tumor? If MHC down-regulation in vivo is epigenetic, then expression in vitro could be misleading. The paper would be substantially strengthened if it were possible to provide some validation of the cell line data using tissue samples.

This is an important point and we do recognise that comparing cell lines to in vivo tumours can be misleading. To address this we have used reverse transcriptase (RT)-PCR to compare the expression of B2m, classical MHC class I and the non-classical class I in the three DFT2 cell lines and the 6 primary tumour samples which were used in the immunohistochemistry (IHC) experiments (Figure 2E). Two of these primary tumours, DFT2_RV and DFT2_SN were used to derive the cell lines analysed in Figure 1 and are key to comparing the flow cytometry, immunohistochemistry and RTPCR results. This data has been added to Figure 2E and the Results section.

We find that the primary tumour samples express B2m, reflecting the B2m cell surface protein and mRNA expression in the cell lines. In addition, the primary tumours express both classical MHC class I and non-classical MHC class I, but this expression appears weaker than the cell lines and variable between the tumours. While variable expression was also overserved in the IHC experiments, it should be noted that we do not consider the RT-PCR quantitative as the amount of stroma (host) will vary in each sample, contributing to the total RNA and potentially affecting transcript levels. This has been noted in the manuscript (subsection “DFT2 cells express classical and non-classical MHC class I heavy chain genes in vitroand in vivo.”).

In this regard, patchiness of the immunohistochemical staining seems odd. Why should there be areas of continued expression and areas where there is loss of expression? Why wouldn't loss of expression be more random? Some of the images seem to show that staining is peripheral in to the tumors (Figure 4—figure supplement 1). Was this the case and why might that be? Because the older sections of the tumor were more likely to have lost expression?

This point is valid and we have performed a review of our immunohistochemistry data to identify regions subject to edge artefact and necrosis of the tumour tissue, which may have given a misleading impression of positive expression. We have re-imaged the sections, avoiding these areas and shown the six different tumours in Figure 3 (rather than as supplementary material) to present these results more clearly.

Figure 3 shows that DFT2 primary tumours can have high expression of the classical class I heavy chains (i.e. DFT2_RV, SN and 818), while others have lower expression (i.e. DFT2_812). Variable expression is also observed for the non-classical MHC class I, Saha-UK. However, the staining indicates that expression may be primarily internal, and this is reflected in the text of the Results section, Figure 3.

In a number of tumours, the staining for the classical MHC class I and non-classical MHC class I (i.e. DFT2_547) is ‘patchy’ we see some areas of the tumour tissue where cells are staining more strongly for the MHC class I proteins. This may be because older sections of the tumour have lost expression, but it may also be due to local environmental factors, signalling and cytokines from host devils. However, further experiments are needed to assess the mechanisms controlling modulation.

There is considerable precedent for this in single organism tumours and we have included for the reviewers some examples of head and neck tumours with a range MHC class I expression, including weak, variable and strong examples (stained with W632, a pan specific HLA antibody). There is also considerable literature on loss of MHC class I molecules through DNA mutations in genes involved in antigen processing and presentation and so called ‘soft’ mutations, usually epigenetic and sometimes rescueable (Restifo et al., 1996; McGranahan et al., 2017). We have referred to this literature in the Discussion section.

Were sequential sections stained with anti-UA, B, C followed by anti-UK to see if staining is common to areas and therefore may be artifact or some evidence of co-staining?

Where possible we have always used serial sections for the staining of class I heavy chains and CD3 (Figure 3 and Figure 4). However, in some cases the tissue architecture is different between sections, particularly in tumours with little fibrous stroma. We have attempted co-staining for the different heavy chains, but as both the classical and non-classical genes are expressed together on cells and the affinity of the antibodies is different, it is difficult to resolve both signals clearly.

2) It is unclear how the authors think it likely DFT2 succeeds in immune evasion. Is it (a) there is nothing to be recognised on DFT2 cells; or (b) the DFT2 cells are immune-suppressive? The suggestion that non-classical MHC class 1 molecules (Saha) are inhibitory appears to be entirely speculative. Can the authors provide further studies that might illuminate the mechanism?

A combination of both a and b. As the reviewers point out below there are many ways in which tumours can actively suppress the immune system, but in this work we have focused on what would be antigenic on the cell surface in the context of MHC class I. Unfortunately, at present we cannot contribute any other data to determine the function of the non-classical MHC class I, this will have to remain speculative. However, we have pointed out in the Discussion section that its non-polymorphic nature means it is unlikely to be a major alloantigen in devils, regardless of function.

In this regard, MHC molecule expression in vivo is recorded as variable. From this the authors conclude that they may be catching immune-editing or evolutionary selection for MHC loss as it happens. This could be true, but it is unpersuasive and very speculative; there is considerable variation in expression and no evidence for emerging dominance of MHC negative variants. Importantly, the authors do not observe infiltration of tumor with lymphocytes which might reflect ongoing selection. How do they reconcile this with their hypothesis about immune evasion and selection?

We agree that we have not shown extensive data on how the devil immune system responds to DFT2 (if it does at all). We have improved this analysis by undertaking more extensive staining for CD3 to screen for infiltrating lymphocytes in the primary tumours (This is now shown in Figure 4). We find that 4 of the 6 primary tumours have CD3 cell infiltrating the tumour (Results section).

2

Previous reports have shown the vast majority of DFT1 tumours are CD3 negative (reflecting the lack of immune response to this tumour) and as we have noted in the text lymphocyte infiltration is associated with a more positive prognostic outcome in many single organism tumours (Chee et al., 2017 and Galon et al., 2006). At present the proposal that DFT2 is losing MHC expression due to an immune response from the host is speculative and we have altered the Discussion section for clarity.

One would expect processing and presentation in the MHC I molecules of minor histocompatibility antigens, at least some of which are expected to differ between the first animal from whom the tumor arose and subsequent recipients. Therefore, other reasons such as a T cell hostile micro-environment despite the presence of minor H differences may play a role in the selection for transmission of the cancer. This could include a variety of mechanisms also reported for immunogenic cancers in autologous hosts:

1) Exclusion of T cells by TGFβ (two recent Nature papers)

2) High numbers of immunosuppressive myeloid cells

3) Lack of the proper chemokines and/ or chemokine receptors

4) Hypoxia

5) IDO expression

The authors are encouraged to discuss this and refer to relevant review papers cataloguing these possibilities for autochthonous tumors. If this is researched further, it may lead to therapeutic possibilities that are also relevant for immunotherapy of cancer in general.

This is a good point and while our current studies have focused on MHC expression in DFT1 and DFT2 this is an area of importance. We have included reference to some of these mechanisms in the Discussion section.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Figure 3—source data 1. Nucleotide sequences for the pET22B + SahaUC and pET22B + SahaUK constructs used to test the specificity of the MHC class I antibodies (a- UA/UB/UC 15-25-18 and a- UK 15-29-1) described in Figure 3.
    elife-35314-fig3-data1.txt (2.1KB, txt)
    DOI: 10.7554/eLife.35314.010
    Table 1–source data 1. MHC class I transcripts expressed in DFT2 and host devils that were used to generate Table 1 and Figure 5.
    elife-35314-table1-data1.txt (6.9KB, txt)
    DOI: 10.7554/eLife.35314.015
    Supplementary file 1. Biological samples used in this study.

    Details of the tumour and host tissue samples, the date the samples were collected from the animal and the location of the animal when it was trapped. *As described previously (Pye et al., 2016b).

    elife-35314-supp1.docx (13.1KB, docx)
    DOI: 10.7554/eLife.35314.016
    Supplementary file 2. Primers used in this study with amplicon size and optimised annealing temperature.
    elife-35314-supp2.docx (13.9KB, docx)
    DOI: 10.7554/eLife.35314.017
    Supplementary file 3. Antibodies used in this study.
    elife-35314-supp3.docx (12.5KB, docx)
    DOI: 10.7554/eLife.35314.018
    Supplementary file 4. PCR conditions for the primers used in this study.
    elife-35314-supp4.docx (13.4KB, docx)
    DOI: 10.7554/eLife.35314.019
    Transparent reporting form
    elife-35314-transrepform.docx (246.5KB, docx)
    DOI: 10.7554/eLife.35314.020

    Data Availability Statement

    All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Table 1, Figure 5 and Figure 3-figure supplement 1.

    The following previously published datasets were used:

    Murchison, author. Devil_ref v7.0 (GCA_000189315.1) 2012 http://www.ensembl.org/Sarcophilus_harrisii/Info/Index Publicly available at the European Nucleotide Archive (accession no: GCA_000189315.1)

    Stammnitz, author. Genomes of Tasmanian devil transmissible cancers DFT1, DFT2 and normal animals. 2018 https://www.ebi.ac.uk/ena/data/view/PRJEB21902 Publicly available at the European Nucleotide Archive (accession no: ENA: PRJEB21902)

    Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd

    RESOURCES